First Eagle Investment Management LLC Buys 59,525 Shares of Enovis Co. (NYSE:ENOV)

First Eagle Investment Management LLC grew its holdings in Enovis Co. (NYSE:ENOV) by 20.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 343,921 shares of the company’s stock after acquiring an additional 59,525 shares during the quarter. First Eagle Investment Management LLC owned 0.60% of Enovis worth $15,091,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Commonwealth Equity Services LLC bought a new stake in Enovis during the fourth quarter worth about $402,000. Swiss National Bank lifted its position in Enovis by 2.5% during the fourth quarter. Swiss National Bank now owns 109,800 shares of the company’s stock worth $4,818,000 after purchasing an additional 2,700 shares during the period. Great Lakes Advisors LLC lifted its position in Enovis by 4.7% during the fourth quarter. Great Lakes Advisors LLC now owns 53,584 shares of the company’s stock worth $2,351,000 after purchasing an additional 2,415 shares during the period. HighTower Advisors LLC bought a new stake in Enovis during the fourth quarter worth about $275,000. Finally, River Road Asset Management LLC lifted its position in Enovis by 3.8% during the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company’s stock worth $54,339,000 after purchasing an additional 45,762 shares during the period. Institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC cut their price objective on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Stock Up 3.4 %

ENOV stock opened at $37.01 on Friday. The stock has a market capitalization of $2.11 billion, a P/E ratio of -16.90 and a beta of 2.05. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12 month low of $35.14 and a 12 month high of $62.79. The firm has a 50-day moving average price of $43.32 and a 200-day moving average price of $43.74.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.